Prognostic Biomarkers in Endometrial Cancer: A Systematic Review and Meta-Analysis

Rubia, Eva Coll-de la; Martínez‐García, Elena; Dittmar, Gunnar; Gil‐Moreno, Antonio; Cabrera, Sílvia; Colás, Eva

doi:10.3390/jcm9061900

Cited by 81 publications

(70 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The risk factors for EC include elevated estrogen levels (caused by obesity, diabetes, and high-fat diets), premature menarche, being non-parturients, late desperate age, Lynch syndrome, grade ≥ 55 years old, and using tamoxifen [3]. The mortality rate of EC is directly related to poor prognostic factors driving tumor recurrence [4]. B-cell translocation gene 1 (BTG1) is a member of the TOB/BTG protein family and is an anti-proliferation gene.…”

Section: Introductionmentioning

confidence: 99%

BTG1 inhibits malignancy as a novel prognosis signature in endometrial carcinoma

Huo

et al. 2020

Cancer Cell Int

View full text Add to dashboard Cite

Background Endometrial carcinoma (EC) is one of the three major malignant tumors of the female reproductive system. In recent years, the incidence and mortality rate of EC have increased. B-cell translocation gene 1 (BTG1) is an anti-proliferation gene that regulates the occurrence and development of a variety of tumors, but there is no research regarding this gene in EC. Methods Based on The Cancer Genome Atlas (TCGA) database, we used a variety of bioinformatics tools and databases to explore the expression and prognosis of BTG1. We verified expression and prognosis of BTG1 in EC using qRT-PCR and analyzed the relevant clinicopathological parameters. We functionally enriched BTG1 and related genes in EC patients through the bioinformatics website and analyzed miRNA targets of BTG1 and interacting protein networks. Cell proliferation, wound healing, transwell invasion, and cell apoptosis assays were used to detect the effects of BTG1 on the malignant biological behavior of endometrial carcinoma cells (ECCs). The effect of BTG1 on the epithelial-to-mesenchymal transition (EMT) process was detected using western blot. Results We analyzed the expression and prognosis of BTG1 based on TCGA and found that low expression of BTG1 was associated with poor EC prognosis. The qRT-PCR suggested that BTG1 had low expression in EC. BTG1 expression was significantly correlated with overall survival (OS) shortening. Clinicopathological analysis suggested that expression of BTG1 was related to invasion depth and the International Federation of Gynecology and Obstetrics (FIGO) stage. EC pathological tissue type, fertility history, lymphatic metastasis, menopause, estrogen receptor (ER), progesterone receptor (PR), and age of diagnosis were not related. Functional enrichment analysis showed that BTG1 plays an important role in regulating embryonic development, tumorigenesis, apoptosis, and cell cycle. Biological behavior experiments suggest that BTG1 inhibits proliferation, migration, and invasion of ECCs, and promotes apoptosis of ECCs. Western blot indicated that BTG1 inhibited the EMT process of ECCs. Conclusions BTG1, as a tumor suppressor gene, plays an important role in the occurrence and development of EC. We believe that BTG1 can be used as a potential prognostic biomarker for EC.

show abstract

Section: Introductionmentioning

confidence: 99%

BTG1 inhibits malignancy as a novel prognosis signature in endometrial carcinoma

Huo

et al. 2020

Cancer Cell Int

View full text Add to dashboard Cite

show abstract

“…EC patients, and CNL and CNH groups are coupled to worse prognosis [13,14]. The implementation of this novel EC classification laid the grounds for the refined differential diagnosis of particular cancer subtypes based on molecular signatures and provided a precision approach for both research and clinical management [5].…”

Section: Introductionmentioning

confidence: 99%

Insulin Resistance and Endometrial Cancer: Emerging Role for microRNA

Sidorkiewicz

Jóźwik

Niemira

et al. 2020

Cancers

View full text Add to dashboard Cite

Endometrial cancer (EC) remains one of the most common cancers of the female reproductive system. Epidemiological and clinical data implicate insulin resistance (IR) and its accompanying hyperinsulinemia as key factors in the development of EC. MicroRNAs (miRNAs) are short molecules of non-coding endogenous RNA that function as post-transcriptional regulators. Accumulating evidence has shown that the miRNA expression pattern is also likely to be associated with EC risk factors. The aim of this work was the verification of the relationships between IR, EC, and miRNA, and, as based on the literature data, elucidation of miRNA’s potential utility for EC prevention in IR patients. The pathways affected in IR relate to the insulin receptors, insulin-like growth factors and their receptors, insulin-like growth factor binding proteins, sex hormone-binding globulin, and estrogens. Herein, we present and discuss arguments for miRNAs as a plausible molecular link between IR and EC development. Specifically, our careful literature search indicated that dysregulation of at least 13 miRNAs has been ascribed to both conditions. We conclude that there is a reasonable possibility for miRNAs to become a predictive factor of future EC in IR patients.

show abstract

“…Risk factors for EC include elevated estrogen levels (caused by obesity, diabetes, and high-fat diets), premature menarche, non-parturients, late desperate age, Lynch syndrome, grade ≥ 55 years old, and using tamoxifen [3] . The mortality rate of EC is directly related to the poor prognostic factors driving tumor recurrence [4] . B-cell translocation gene 1 (BTG1) is a member of the TOB/BTG protein family and is an anti-proliferation gene.…”

Section: Introductionmentioning

confidence: 99%

BTG1 inhibits malignancy as a novel prognosis signature in endometrial carcinoma

Huo

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Endometrial carcinoma (EC) is one of the three major malignant tumors of the female reproductive system. In recent years, the incidence and mortality rate of EC have increased. B-cell translocation gene 1 (BTG1) is an anti-proliferation gene that regulates the occurrence and development of a variety of tumors, but there is no research regarding this gene in EC.Methods: Based on The Cancer Genome Atlas (TCGA) database, we used a variety of bioinformatics tools and databases to explore the expression and prognosis of BTG1. We verified expression and prognosis of BTG1 in EC using qRT-PCR and analyzed the relevant clinicopathological parameters. We functionally enriched BTG1 and related genes in EC patients through the bioinformatics website and analyzed miRNA targets of BTG1 and interacting protein networks. Cell proliferation, wound healing, transwell invasion, and cell apoptosis assays were used to detect the effects of BTG1 on the malignant biological behavior of endometrial carcinoma cells (ECCs). The effect of BTG1 on the epithelial-to-mesenchymal transition (EMT) process was detected using western blot.Results: We analyzed the expression and prognosis of BTG1 based on TCGA and found that low expression of BTG1 was associated with poor EC prognosis. The qRT-PCR suggested that BTG1 had low expression in EC. BTG1 expression was significantly correlated with overall survival (OS) shortening. Clinicopathological analysis suggested that expression of BTG1 was related to invasion depth and the International Federation of Gynecology and Obstetrics (FIGO) stage. EC pathological tissue type, fertility history, lymphatic metastasis, menopause, estrogen receptor (ER), progesterone receptor (PR), and age of diagnosis were not related. Functional enrichment analysis showed that BTG1 plays an important role in regulating embryonic development, tumorigenesis, apoptosis, and cell cycle. Biological behavior experiments suggest that BTG1 inhibits proliferation, migration, and invasion of ECCs, and promotes apoptosis of ECCs. Western blot indicated that BTG1 inhibited the EMT process of ECCs.Conclusions: BTG1 plays an important role in the occurrence and development of EC. BTG1, as a tumor suppressor gene, shows low expression in EC, which can inhibit malignant biological behavior and EMT process of ECCs. In addition, BTG1 can be used as a potential prognostic biomarker for EC.

show abstract

Prognostic Biomarkers in Endometrial Cancer: A Systematic Review and Meta-Analysis

Cited by 81 publications

References 77 publications

BTG1 inhibits malignancy as a novel prognosis signature in endometrial carcinoma

BTG1 inhibits malignancy as a novel prognosis signature in endometrial carcinoma

Insulin Resistance and Endometrial Cancer: Emerging Role for microRNA

BTG1 inhibits malignancy as a novel prognosis signature in endometrial carcinoma

Contact Info

Product

Resources

About